PDUFA target action date set to 10 June 2026 LUND, Sweden, Jan. 9, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and ...
US FDA accepts Camurus’ resubmission of NDA for Oclaiz for treatment of acromegaly: Lund, Sweden Monday, January 12, 2026, 15:00 Hrs [IST] Camurus, an international, science-led ...
Oclaiz is a subcutaneous long-acting octreotid depot, designed for optimized disease control and convenient self-administration. The product is based on Camurus' FluidCrystal technology and is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback